Conflict of interest statement
The authors have no conflicts of interest to report.
1. Ghigo A, Prono G, Riccardi E, De Rose V. Dysfunctional inflammation in cystic fibrosis airways: From mechanisms to novel therapeutic approaches. Int J Mol Sci . 2021;22(4):1-23. doi:10.3390/ijms22041952
2. Roesch EA, Nichols DP, Chmiel JF. Inflammation in cystic fibrosis: An update. Pediatr Pulmonol . 2018;53(June):S30-S50. doi:10.1002/ppul.24129
3. Rowe SM, Heltshe SL, Gonska T, et al. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. Am J Respir Crit Care Med . 2014;190(2):175-184. doi:10.1164/rccm.201404-0703OC
4. McNally P, Butler D. Ivacaftor and Airway Inflammation in Preschool Children with Cystic Fibrosis. Am J Respir Crit Care Med . 2021;204(5):605-607.
5. Veltman M, De Sanctis JB, Stolarczyk M, et al. CFTR Correctors and Antioxidants Partially Normalize Lipid Imbalance but not Abnormal Basal Inflammatory Cytokine Profile in CF Bronchial Epithelial Cells.Front Physiol . 2021;12(February). doi:10.3389/fphys.2021.619442
6. Nichols DP, Paynter AC, Heltshe SL, et al. Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial. Am J Respir Crit Care Med . 2022;205(5):529-539. doi:10.1164/rccm.202108-1986oc